CR20220531A - Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados - Google Patents
Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivadosInfo
- Publication number
- CR20220531A CR20220531A CR20220531A CR20220531A CR20220531A CR 20220531 A CR20220531 A CR 20220531A CR 20220531 A CR20220531 A CR 20220531A CR 20220531 A CR20220531 A CR 20220531A CR 20220531 A CR20220531 A CR 20220531A
- Authority
- CR
- Costa Rica
- Prior art keywords
- relates
- proteins
- antibodies
- enzyme
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
Abstract
La presente invención se refiere a proteínas, en particular, anticuerpos, tales como anticuerpos biespecíficos anti-CD20/anti-CD3 y anticuerpos anti-α-sinucleína, que tienen glucanos monogalactosilados (G1) y digalactosilados (G2). Más en particular, la presente invención se refiere a ingeniería de galactosilación para generar proteínas con propiedades terapéuticas mejoradas, que incluyen proteínas con título aumentado. Además, la invención se refiere a un medio de cultivo celular y una célula de mamífero, así como a métodos que usan dicho medio de cultivo celular y dicha célula de mamífero para producir dichas proteínas. Además, la presente invención se refiere al uso de dichos anticuerpos como un medicamento, tal como para el tratamiento de cáncer, en particular, cáncer asociado a linfocitos B, o enfermedad de Parkinson.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20171356 | 2020-04-24 | ||
PCT/EP2021/060637 WO2021214277A1 (en) | 2020-04-24 | 2021-04-23 | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220531A true CR20220531A (es) | 2022-11-28 |
Family
ID=70464886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220531A CR20220531A (es) | 2020-04-24 | 2021-04-23 | Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230265204A1 (es) |
EP (1) | EP4139349A1 (es) |
JP (1) | JP2023522417A (es) |
KR (1) | KR20230005172A (es) |
CN (1) | CN115427443A (es) |
AR (1) | AR121918A1 (es) |
AU (1) | AU2021258475A1 (es) |
BR (1) | BR112022021203A2 (es) |
CA (1) | CA3178472A1 (es) |
CL (1) | CL2022002885A1 (es) |
CR (1) | CR20220531A (es) |
IL (1) | IL296664A (es) |
MX (1) | MX2022013173A (es) |
PE (1) | PE20230078A1 (es) |
TW (1) | TW202206459A (es) |
WO (1) | WO2021214277A1 (es) |
ZA (1) | ZA202210643B (es) |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3334167A1 (de) | 1983-09-21 | 1985-04-04 | Siemens AG, 1000 Berlin und 8000 München | Halbleiterdiode |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
NZ267842A (en) | 1993-05-28 | 1997-09-22 | Baylor College Medicine | Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
JP2002502086A (ja) | 1998-01-23 | 2002-01-22 | アナリティカ オブ ブランフォード インコーポレーテッド | 表面からの質量分光測定 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
ES2402527T3 (es) * | 2001-12-27 | 2013-05-06 | Glycofi, Inc. | Procedimientos para obtener estructuras de carbohidrato de tipo mamífero mediante ingeniería genética |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
LT2520590T (lt) | 2007-04-03 | 2018-09-10 | Amgen Research (Munich) Gmbh | Susijusioms rūšims specifinis rišantis domenas |
CN101815786A (zh) | 2007-10-12 | 2010-08-25 | 弗·哈夫曼-拉罗切有限公司 | 来自多个核酸的蛋白质表达 |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
SI2949666T1 (sl) | 2008-12-19 | 2019-03-29 | Biogen International Neuroscience Gmbh | Človeška anti alfa-sinukleinska protitelesa |
KR20110013687A (ko) | 2009-08-03 | 2011-02-10 | 삼성모바일디스플레이주식회사 | 유기전계발광표시장치 및 그의 구동방법 |
RU2015153109A (ru) | 2009-09-16 | 2019-01-15 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применения |
CA2839563C (en) | 2011-06-23 | 2019-10-29 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
EP2771031B1 (en) | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
NZ629296A (en) | 2012-01-27 | 2016-06-24 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
AU2014351996B2 (en) | 2013-11-21 | 2020-01-02 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
PE20170263A1 (es) | 2014-08-04 | 2017-03-30 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
TW201902512A (zh) * | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療方法 |
WO2019020606A1 (en) * | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY |
CN112839710A (zh) * | 2018-08-09 | 2021-05-25 | 霍夫曼-拉罗奇有限公司 | 帕金森氏病的确定 |
-
2021
- 2021-04-23 MX MX2022013173A patent/MX2022013173A/es unknown
- 2021-04-23 KR KR1020227036931A patent/KR20230005172A/ko active Search and Examination
- 2021-04-23 PE PE2022002437A patent/PE20230078A1/es unknown
- 2021-04-23 EP EP21719678.1A patent/EP4139349A1/en active Pending
- 2021-04-23 IL IL296664A patent/IL296664A/en unknown
- 2021-04-23 CA CA3178472A patent/CA3178472A1/en active Pending
- 2021-04-23 TW TW110114642A patent/TW202206459A/zh unknown
- 2021-04-23 WO PCT/EP2021/060637 patent/WO2021214277A1/en active Application Filing
- 2021-04-23 CN CN202180029319.5A patent/CN115427443A/zh active Pending
- 2021-04-23 AU AU2021258475A patent/AU2021258475A1/en active Pending
- 2021-04-23 AR ARP210101087A patent/AR121918A1/es unknown
- 2021-04-23 CR CR20220531A patent/CR20220531A/es unknown
- 2021-04-23 JP JP2022564304A patent/JP2023522417A/ja active Pending
- 2021-04-23 BR BR112022021203A patent/BR112022021203A2/pt unknown
- 2021-04-23 US US17/996,807 patent/US20230265204A1/en active Pending
-
2022
- 2022-09-26 ZA ZA2022/10643A patent/ZA202210643B/en unknown
- 2022-10-18 CL CL2022002885A patent/CL2022002885A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4139349A1 (en) | 2023-03-01 |
MX2022013173A (es) | 2022-11-30 |
KR20230005172A (ko) | 2023-01-09 |
WO2021214277A1 (en) | 2021-10-28 |
US20230265204A1 (en) | 2023-08-24 |
CL2022002885A1 (es) | 2023-06-16 |
JP2023522417A (ja) | 2023-05-30 |
ZA202210643B (en) | 2023-06-28 |
TW202206459A (zh) | 2022-02-16 |
PE20230078A1 (es) | 2023-01-11 |
AR121918A1 (es) | 2022-07-20 |
BR112022021203A2 (pt) | 2022-12-06 |
IL296664A (en) | 2022-11-01 |
AU2021258475A1 (en) | 2022-10-20 |
CN115427443A (zh) | 2022-12-02 |
CA3178472A1 (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bayer | An overview of monoclonal antibodies | |
Cho et al. | Engineering advanced logic and distributed computing in human CAR immune cells | |
TWI721959B (zh) | 治療急性骨髓性白血病之抗cd38抗體 | |
CN103118706B (zh) | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl | |
EP2548574B1 (en) | New humanized anti-cd20 monoclonal antibody | |
UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
EP3530736A3 (en) | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics | |
BRPI0514199A (pt) | método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 | |
CN105828837A (zh) | 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法 | |
BRPI0412153B8 (pt) | anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal | |
CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
BRPI0316779B1 (pt) | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados | |
US10414814B2 (en) | Tumor-selective CTLA-4 antagonists | |
CN107207591A (zh) | 血脑屏障受体抗体及使用方法 | |
CN112867503A (zh) | 掩蔽的细胞因子缀合物 | |
CN110352063A (zh) | 精氨酸酶抑制剂组合疗法 | |
CN107810012A (zh) | 使用抗il‑34抗体治疗神经疾病的组合物和方法 | |
EA202092459A1 (ru) | Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают | |
MX2021010061A (es) | Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1. | |
MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
TW201920659A (zh) | 用於治療免疫療法的副作用之方法 | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
CR20220531A (es) | Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados | |
MX2022008901A (es) | Conjugados de proteinas-compuestos antivirales. | |
Hidalgo et al. | Switchable CAR T cell strategy against osteosarcoma |